OnCo

Post-transplant lymphoproliferative disorder (PTLD): lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersFRαRisk group
Early / localised··1
Advanced, first line1··
Third line and beyond·1·
Other settings1··

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupAfter allogeneic HSCT, high riskWeekly plasma EBV DNA monitoring with pre-emptive rituximab when load rises; reduction of immunosuppression where possible.87

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAll PTLD, first stepReduce immunosuppression as far as graft safety allows, with close monitoring for rejection; surgery or radiotherapy for localised disease.

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
FRαEBV-positive, relapsed or refractoryEBV-specific T cells: tabelecleucel (EMA approval 2022; under FDA review) or institutional virus-specific T-cell programmes; clinical trials.37

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersCD20-positive PTLD not responding to reduced immunosuppressionRituximab weekly for four doses; patients in complete remission continue rituximab consolidation alone, others proceed to R-CHOP (PTLD-1 risk-stratified sequential treatment).83

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.